

Stanford

Rahel Roudi

Basic Life Research Scientist, Rad/Pediatric Radiology

Bio

BIO

Rahel Roudi is a research scientist in the Department of Radiology at Stanford University. Dr. Roudi trained at the Iran University of Medical Sciences, Iran. She worked as an Assistant Professor at the Iran University of Medical Sciences, Iran from 2015 to 2019, before coming to the United States. During this time, Dr. Roudi worked on several projects which have led to successful collaborations with the Karolinska Institute; Charite Universitätsmedizin Berlin; Oslo University Hospital; National University of Singapore; Shanghai University of Traditional Chinese Medicine and University of Brescia, among other internationally recognized institutions. Dr. Roudi was a visiting scientist in the University of Texas at San Antonio and then appointed as a postdoctoral associate at the University of Minnesota for one year, before joining Stanford University in 2022.

Her research interest focuses on the molecular oncology and immunotherapies of solid tumors and she published more than 40 peer reviewed papers.

Publications

PUBLICATIONS

- **Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects.** *International immunopharmacology*
Roudi, R., D'Angelo, A., Sirico, M., Sobhani, N.
2021; 101 (Pt A): 108322
- **p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis.** *Molecules (Basel, Switzerland)*
Sobhani, N., Roviello, G., D'Angelo, A., Roudi, R., Neeli, P. K., Generali, D.
2021; 26 (20)
- **Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.** *Immunotherapy*
Petrilli, F., Ferrara, R., Signorelli, D., Ghidini, A., Proto, C., Roudi, R., Sabet, M. N., Facelli, S., Garassino, M. C., Luciani, A., Roviello, G.
2021; 13 (7): 621-631
- **CTLA-4 in Regulatory T Cells for Cancer Immunotherapy.** *Cancers*
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., Li, Y.
2021; 13 (6)
- **Immunotherapy-based combinations versus standard first-line and hypothyroidism risk.** *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*
Roviello, G., Villari, D., Roudi, R.
2020; 22 (9): 1664-1665
- **Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients.** *Molecular & cellular oncology*
Roudi, R., Barodabi, M., Madjd, Z., Roviello, G., Corona, S. P., Panahei, M.
2020; 7 (5): 1788366
- **Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer.** *Cancer cell international*
Vafaei, S., Roudi, R., Madjd, Z., Aref, A. R., Ebrahimi, M.
2020; 20: 288
- **Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape.** *Journal of cellular physiology*

- Mohsenzadegan, M., Peng, R. W., Roudi, R.
2020; 235 (1): 74-86
- **Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics.** *Frontiers in oncology*
Saeednejad Zanjani, L., Madjd, Z., Rasti, A., Asgari, M., Abolhasani, M., Tam, K. J., Roudi, R., Mælandsmo, G. M., Fodstad, Ø., Andersson, Y.
2019; 9: 1302
 - **High GD2 expression defines breast cancer cells with enhanced invasiveness.** *Experimental and molecular pathology*
Mansoori, M., Roudi, R., Abbasi, A., Abolhasani, M., Abdi Rad, I., Sharifabrizi, A., Madjd, Z.
2019; 109: 25-35
 - **Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights.** *Journal of oncology*
Roviello, G., D'Angelo, A., Roudi, R., Petrioli, R., Mini, E.
2019; 2019: 5692317
 - **Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.** *Future oncology (London, England)*
Tartarone, A., Roviello, G., Lerose, R., Roudi, R., Aieta, M., Zoppoli, P.
2019; 15 (20): 2423-2433
 - **Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.** *BMC cancer*
Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., Li, B., Li, X.
2019; 19 (1): 558
 - **Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.** *International journal of experimental pathology*
Kalantari, E., Abolhasani, M., Roudi, R., Farajollahi, M. M., Farhad, S., Madjd, Z., Askarian-Amiri, S., Mohsenzadegan, M.
2019; 100 (2): 123-132
 - **Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy.** *Cancer biotherapy & radiopharmaceuticals*
Roviello, G., Corona, S. P., Aieta, M., Roudi, R.
2019; 34 (3): 141-146
 - **CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer.** *Biomarkers in medicine*
Sadeghi, A., Roudi, R., Mirzaei, A., Zare Mirzaei, A., Madjd, Z., Abolhasani, M.
2019; 13 (6): 419-426
 - **Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma.** *Frontiers in oncology*
Zhou, J. G., Zhong, H., Zhang, J., Jin, S. H., Roudi, R., Ma, H.
2019; 9: 78
 - **Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma.** *Bratislavské lekarske listy*
Korourian, A., Madjd, Z., Roudi, R., Sharifabrizi, A., Soleimani, M.
2019; 120 (1): 35-39
 - **Association of homeobox B13 (HOXB13) gene variants with prostate cancer risk in an Iranian population.** *Medical journal of the Islamic Republic of Iran*
Roudi, R., Nemati, H., Rastegar Moghadam, M., Sotoudeh, M., Narouie, B., Shojaei, A.
2018; 32: 97
 - **Do statins improve outcomes for patients with non-small cell lung cancer? A systematic review and meta-analysis protocol.** *BMJ open*
Li, F., Liu, G., Roudi, R., Huang, Q., Swierzy, M., Ismail, M., Zhao, S., Rueckert, J. C.
2018; 8 (9): e022161
 - **Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.** *PloS one*
Fathi, Z., Mousavi, S. A., Roudi, R., Ghazi, F.
2018; 13 (7): e0200633
 - **Molecular epidemiology of lung cancer in Iran: implications for drug development and cancer prevention.** *Journal of human genetics*
Fathi, Z., Syn, N. L., Zhou, J. G., Roudi, R.

2018; 63 (7): 783-794

● **Resisting resistance to cancer immunotherapy. Thoracic cancer**

Lam, W. S., Wang, L. Z., Roudi, R., Yong, W. P., Syn, N. L., Sundar, R.
2018; 9 (5): 507-508

● **Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? Clinical and experimental medicine**

Roviello, G., Zanotti, L., Cappelletti, M. R., Gobbi, A., Dester, M., Paganini, G., Pacifico, C., Generali, D., Roudi, R.
2018; 18 (1): 15-20

● **Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. The Cochrane database of systematic reviews**

Zhu, J., Li, R., Tisellius, E., Roudi, R., Teghararian, O., Suo, C., Song, H.
2017; 12: CD011300

● **Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. Cancer biomarkers : section A of Disease markers**

Kalantari, E., Asadi Lari, M. H., Roudi, R., Korourian, A., Madjd, Z.
2017; 20 (4): 563-573

● **MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Experimental biology and medicine (Maywood, N.J.)**

Korourian, A., Roudi, R., Shariftabrizi, A., Madjd, Z.
2017; 242 (18): 1842-1847

● **DNA Microarray for Rapid Detection and Identification of Food and Water Borne Bacteria: From Dry to Wet Lab. The open microbiology journal**

Ranjbar, R., Behzadi, P., Najafi, A., Roudi, R.
2017; 11: 330-338

● **Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis. Medicine**

Sun, X., Roudi, R., Chen, S., Fan, B., Li, H. J., Zhou, M., Li, X., Li, B.
2017; 96 (44): e8407

● **Differential role of Wnt signaling and base excision repair pathways in gastric adenocarcinoma aggressiveness. Clinical and experimental medicine**

Korourian, A., Roudi, R., Shariftabrizi, A., Kalantari, E., Sotoodeh, K., Madjd, Z.
2017; 17 (4): 505-517

● **Antimicrobial Peptides As Biologic and Immunotherapeutic Agents against Cancer: A Comprehensive Overview. Frontiers in immunology**

Roudi, R., Syn, N. L., Roudbary, M.
2017; 8: 1320

● **Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients. Applied immunohistochemistry & molecular morphology : AIMM**

Kalantari, E., Saadi, F. H., Asgari, M., Shariftabrizi, A., Roudi, R., Madjd, Z.
2017; 25 (8): 592-598

● **Cancer stem cell research in Iran: potentials and challenges. Future oncology (London, England)**

Roudi, R., Ebrahimi, M., Shariftabrizi, A., Madjd, Z.
2017; 13 (20): 1809-1826

● **Lung cancer and #-glucans: review of potential therapeutic applications. Investigational new drugs**

Roudi, R., Mohammadi, S. R., Roudbary, M., Mohsenzadegan, M.
2017; 35 (4): 509-517

● **Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. Pathology, research and practice**

Foroozan, M., Roudi, R., Abolhasani, M., Gheytanchi, E., Mehrazma, M.
2017; 213 (6): 612-618

● **Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Applied immunohistochemistry & molecular morphology : AIMM**

Sedaghat, S., Gheytanchi, E., Asgari, M., Roudi, R., Keymoosi, H., Madjd, Z.
2017; 25 (3): 196-202

- **Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma.** *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*
Roudi, R., Madjd, Z., Ebrahimi, M., Najafi, A., Korourian, A., Shariftabrizi, A., Samadikuchaksaraei, A.
2016; 37 (9): 11843-11859
- **Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer;a tissue microarray analysis.** *Journal of cancer research and therapeutics*
Roudi, R., Haji, G., Madjd, Z., Shariftabrizi, A., Mehrazma, M.
2016; 12 (2): 1065-9
- **Comparative expression analysis of putative cancer stem cell markers CD44 and ALDH1A1 in various skin cancer subtypes.** *The International journal of biological markers*
Erfani, E., Roudi, R., Rakhshan, A., Sabet, M. N., Shariftabrizi, A., Madjd, Z.
2016; 31 (1): e53-61
- **Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol.** *BMJ open*
Rasti, A., Mehrazma, M., Madjd, Z., Keshtkar, A. A., Roudi, R., Babashah, S.
2016; 6 (1): e009667
- **Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells.** *Future oncology (London, England)*
Roudi, R., Ebrahimi, M., Sabet, M. N., Najafi, A., Nourani, M. R., Fomeshi, M. R., Samadikuchaksaraei, A., Shariftabrizi, A., Madjd, Z.
2015; 11 (17): 2383-93
- **Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.** *Cancer investigation*
Roudi, R., Korourian, A., Shariftabrizi, A., Madjd, Z.
2015; 33 (7): 294-302
- **Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer.** *Cancer biomarkers : section A of Disease markers*
Roudi, R., Madjd, Z., Korourian, A., Mehrazma, M., Molanae, S., Sabet, M. N., Shariftabrizi, A.
2014; 14 (6): 457-67
- **CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.** *Cellular & molecular biology letters*
Roudi, R., Madjd, Z., Ebrahimi, M., Samani, F. S., Samadikuchaksaraei, A.
2014; 19 (1): 23-36